Multiple System Atrophy — Research Summary
Printed from RareWays (rareways.com.au) on 27 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Ferroptosis-STING co-activation drives GzmB
Zhu Xiongjie et al. — Biomaterials (1 November 2026)
https://pubmed.ncbi.nlm.nih.gov/42061111/
- 2.
An Abraxane-based albumin nanoplatform loaded with a STING agonist for synergistic dual immunotherapy of triple-negative breast cancer.
Cao Zhen et al. — Biomaterials advances (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42218104/
- 3.
Machine learning to diagnose, classify and predict phenoconversion in isolated REM sleep behavior disorder.
Raheel Kausar et al. — Sleep medicine reviews (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42068794/
- 4.
Hepatic dysfunction and long-term risk of neurodegenerative diseases: A UK Biobank-based analysis.
Su Wei-Ming et al. — Archives of gerontology and geriatrics (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42025146/
- 5.
Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease: Experience from a Single Center in the Middle East.
Maghrabi Ashraf et al. — Journal of laparoendoscopic & advanced surgical techniques. Part A (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42011658/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Multiple System Atrophy
Multiple System Atrophy is a rare and fatal neurodegenerative disease that affects movement, balance, and the autonomic nervous system. It is characterised by alpha-synuclein deposits in glial cells. MSA progresses faster than Parkinson's disease, with median survival of 6-10 years from symptom onset. Diagnosis is challenging and often delayed.
Most Recent Research
The immunosuppressive tumor microenvironment (TME) of B-cell lymphoma limits the efficacy of conventional chemotherapy and hampers the full activation of antitumor immunity. Here, we report a tumor cell membrane-camouflaged nanoplatform (CM@HFeS/DOX/MSA-2) that couples ferroptosis amplification with cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway activation to overcome these barriers. The HFeS nanozyme promotes lipid peroxidation (LPO) and reactive oxygen species (ROS) generation, while doxorubicin (DOX) augments immunogenic cell death (ICD) and facilitates cytosolic DNA accumulation, thereby potentiating MSA-2-mediated STING activation. In vitro and in vivo, CM@HFeS/DOX/MSA-2 synergistically induces ferroptosis, enhances ICD hallmarks, and drives robust dendritic cell (DC) maturation. In an A20 B-cell lymphoma model, this biomimetic nanoplatform markedly suppresses tumor growth, increases intratumoral CD8+ T-cell and DC infiltration, and reduces immunosuppressive macrophages. Imaging mass cytometry and transcriptomic profiling further identify granzyme B (GzmB)+CD38+CD8+T cells and major histocompatibility complex class II (MHCII)+CD103+ CD4+T cells as key effector populations within the remodeled TME. Immune cell depletion experiments support a critical role for CD8+ T cells and the DC-associated immune axis in mediating therapeutic efficacy. Moreover, CM@HFeS/DOX/MSA-2 sensitizes tumors to anti-programmed cell death protein 1 (PD-1) checkpoint blockade and confers strong vaccine-like protection in tumor rechallenge models. Together, this study presents a rationally engineered nanoplatform that coordinately activates ferroptosis and cGAS-STING signaling to reprogram the lymphoma immune landscape and achieve robust, durable antitumor immunity.
Common Questions
What is Multiple System Atrophy?
Multiple System Atrophy is a rare and fatal neurodegenerative disease that affects movement, balance, and the autonomic nervous system. It is characterised by alpha-synuclein deposits in glial cells. MSA progresses faster than Parkinson's disease, with median survival of 6-10 years from symptom onset. Diagnosis is challenging and often delayed.
How many clinical trials are available for Multiple System Atrophy?
RareWays currently indexes 173 clinical trials for Multiple System Atrophy, of which 55 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Multiple System Atrophy come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Multiple System Atrophy.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.